Novel anti-CD33 immunoconjugate demonstrating in vitro and in vivo activity against human acute myeloid leukemia (AML) cells.

被引：0
|
作者：
Hebib, Nadia C.
Larochelle, Fannie
Lutz, Bob
Lambert, John
Blattler, Walter
Roy, Denis Claude
机构：
[1] Hop Maisonneuve Rosemont Res Ctr, Montreal, PQ, Canada
[2] ImmunoGen Inc, Cambridge, MA USA
来源：
CANCER RESEARCH | 2006年 / 66卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5558
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Anti-CD33 monoclonal antibodies enhance the cytotoxic effects of cytosine arabinoside and idarubicin on acute myeloid leukemia cells through similarities in their signaling pathways
    Balaian, L
    Ball, ED
    EXPERIMENTAL HEMATOLOGY, 2005, 33 (02) : 199 - 211
  • [42] Monocyte-mediated lysis of acute myeloid leukemia cells in the presence of the bispecific antibody 251x22 (Anti-CD33 x Anti-CD64)
    Chen, J
    Zhou, JH
    Ball, ED
    CLINICAL CANCER RESEARCH, 1995, 1 (11) : 1319 - 1325
  • [43] In Vitro and In Vivo Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia
    Hagemann, Urs B.
    Wickstroem, Katrine
    Wang, Ellen
    Shea, Adam O.
    Sponheim, Kristine
    Karlsson, Jenny
    Bjerke, Roger M.
    Ryan, Olav B.
    Cuthbertson, Alan S.
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (10) : 2422 - 2431
  • [44] Experimental therapy of leukemia cells with [At-211]anti-CD33 antibodies in vitro overcomes resistance to gemtuzumab ozogamicin
    Petrich, T.
    Korkmaz, Z.
    Krull, D.
    Froemke, C.
    Meyer, G. J.
    Knapp, W. H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S310 - S310
  • [45] Novel Therapeutic Approach to Improve Hematopoiesis By Targeting Myeloid Derived Suppressor Cells with a Humanized Anti-CD33 Antibody
    Eksioglu, Erika A.
    Heider, Karl-Heinz
    Rueter, Bjoern
    Burnette, Alexis
    Wei, Max
    McGraw, Kathy
    Basiorka, Ashley A.
    Patel, Parthik
    Lancet, Jeffrey
    Komrokji, Rami
    List, Alan F.
    Wei, Sheng
    BLOOD, 2014, 124 (21)
  • [46] Cytotoxicity of anti-CD64-ricin A chain immunotoxin against human acute myeloid leukemia cells in vitro and in SCID mice
    Zhong, RK
    Van De Winkel, JGJ
    Thepen, T
    Schultz, LD
    Ball, ED
    JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, 2001, 10 (01): : 95 - 105
  • [47] The Novel BET Inhibitor PLX51107 Has In Vitro and In Vivo Activity Against Acute Myeloid Leukemia
    Grieselhuber, Nicole R.
    Mitchell, Shaneice R.
    Orwick, Shelley
    Harrington, Bonnie K.
    Goettl, Virginia M.
    Walker, Alison R.
    Bhatnagar, Bhavana
    Mims, Alice S.
    Klisovic, Rebecca B.
    Vasu, Sumithra
    Blum, William
    Blachly, James S.
    Lucas, David M.
    Garzon, Ramiro
    Lapalombella, Rosa
    Byrd, John C.
    BLOOD, 2016, 128 (22)
  • [48] CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia
    Kenderian, S. S.
    Ruella, M.
    Shestova, O.
    Klichinsky, M.
    Aikawa, V.
    Morrissette, J. J. D.
    Scholler, J.
    Song, D.
    Porter, D. L.
    Carroll, M.
    June, C. H.
    Gill, S.
    LEUKEMIA, 2015, 29 (08) : 1637 - 1647
  • [49] CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia
    S S Kenderian
    M Ruella
    O Shestova
    M Klichinsky
    V Aikawa
    J J D Morrissette
    J Scholler
    D Song
    D L Porter
    M Carroll
    C H June
    S Gill
    Leukemia, 2015, 29 : 1637 - 1647
  • [50] Phase III trial of a humanized anti-CD33 antibody (HuM195) in patients with relapsed or refractory acute myeloid leukemia
    Gibson, AD
    CLINICAL LYMPHOMA, 2002, 3 (01): : 18 - 19
12345